Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Psilera›
Analysis
AddedFeb 16, 2024
UpdatedJun 1, 2026
Psilera

Psilera

Seed

Psilera pioneers next-generation neuroplastogens and psychedelic therapies, advancing PSIL-006 toward first-in-human trials in 2027 following an $8.8M Series Seed extension.

HQ
Tampa, FL, US
Founded
2019
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Website

Contents

  1. 01Executive Summary
  2. 02Products & Services
  3. 03Market Outlook
  4. 04Competitive Strengths
  1. 01Executive Summary
  2. 02Products & Services
  3. 03Market Outlook
  4. 04Competitive Strengths

Memo

Psilera closed an oversubscribed $8.8 million Series Seed extension in May 2026, led by a syndicate of institutional and strategic investors. The funding will advance PSIL-006 toward first-in-human trials in 2027 and support the company's transition from discovery-stage to clinical-stage operations.

Key milestones include the appointment of Dr. Magali Haas as Chief Medical Officer, receipt of up to $2 million in NIH funding for IND-enabling studies, and execution of a strategic DMT patent licensing agreement with AtaiBeckley. The company continues to advance its wholly owned pipeline of novel therapeutic neuroplastogens through next-generation precision neuropharmacology.

Product Overview

PSIL-006 is Psilera's lead clinical asset, a first-in-class neuroplastogen designed to harness therapeutic benefits of traditional psychedelic compounds while minimizing hallucinogenic effects and cardiovascular risks. The compound targets neurological and psychiatric disorders with a precision neuropharmacology approach.

Unlike first-generation psychedelic therapies requiring supervised administration, PSIL-006 is engineered for integration into conventional healthcare systems. The company plans to advance PSIL-006 into first-in-human trials in 2027, supported by an NIH funding award of up to $2 million for IND-enabling studies in alcohol use disorder.

Market Outlook

The neuroplastogen market represents a rapidly evolving segment within psychedelic-inspired medicine, attracting increasing investor and regulatory interest. The 2026 White House executive order on accelerating medical treatments for serious mental illness signals growing federal support for innovative psychiatric therapies.

Neuroplastogens are increasingly viewed as commercially attractive because they may avoid logistical and regulatory complexities associated with hallucinogenic therapies. Companies capable of combining differentiated chemistry, defensible IP, and clinically practical treatment models are positioned for pharmaceutical partnership opportunities.

Competitive Advantages

Psilera has built a best-in-class proprietary compound library covering over one million novel compounds across six serotonergic compound families, with 13 patents filed and two issued by the USPTO. This deep intellectual property portfolio creates significant barriers to entry in the neuroplastogen space.

The company's leadership brings over 100 years of combined experience in biotech and pharmaceutical industries, with co-founders who have created over $1.5 billion in cumulative value from prior startups. Recent strategic moves, including the licensing agreement with AtaiBeckley for DMT patents, further strengthen its competitive position.